Sensodyne's Sensitivity Awareness Communication Strategy

Industry & Competitive Context

Sensodyne operates within the global toothpaste and broader oral healthcare category, a market environment now managed by Haleon plc, the standalone consumer healthcare company demerged from GlaxoSmithKline (GSK) in July 2022. At the time of the demerger, GSK described the consumer healthcare sector into which Haleon entered as a roughly £150 billion global market, characterized by strong demand from an ageing population, an expanding middle class, and unmet consumer health needs. Haleon's public offering documents (Form F-1 and related SEC filings, 2022) describe the Group as "one of a small number of global players" in toothpaste, ranked second worldwide by brand, and the global market leader in Denture Care. Within this category, Sensodyne is positioned specifically around the sub-segment of dentin hypersensitivity treatment. According to Haleon's own regulatory filings, tooth sensitivity is a widespread but under-treated condition: "nearly one third of the global population" reports symptoms of sensitivity, yet "only one third of sufferers purchase a sensitivity toothpaste." This gap between prevalence and category purchase is presented by the company as the central commercial opportunity underlying its communications strategy — the market is less about winning share from a competitor's sensitivity toothpaste and more about converting non-purchasers of the sub-category altogether. Sensodyne's competitive set therefore spans two levels: mainstream toothpaste brands competing for general oral care spend, and dedicated sensitivity-relief entrants competing for the smaller, purchase-converted segment. Haleon's SEC filings note the Group's oral care portfolio also includes parodontax (gum health) and Polident/Poligrip (denture care), which the company refers to collectively as "Power Brands" that receive concentrated marketing investment.

Brand Situation Prior to Campaign

Sensodyne was first marketed in 1961 as a desensitizing toothpaste based on a strontium chloride formulation, later reformulated around potassium nitrate and, in some products, calcium sodium phosphosilicate (branded Novamin) as active ingredients for sensitivity relief. Ownership passed through Block Drug, to SmithKline Beecham (which became GSK) following a 2000 acquisition, and finally to Haleon upon its 2022 demerger from GSK. Public filings describe Sensodyne, prior to and through the demerger period, as already "the brand most associated by consumers with the care of sensitive teeth across virtually all of its key markets" and as holding the position of "number one dentist-recommended toothpaste worldwide for sensitivity." This professional-endorsement equity is documented as a long-standing asset rather than one introduced by a single campaign: Haleon's public materials describe relationships with "more than three million healthcare professionals worldwide" as a proprietary capability supporting the Oral Health portfolio. Despite this endorsement strength, the company's own disclosures frame the brand's core challenge as one of category-level under-penetration rather than share loss to named competitors: two-thirds of people who experience sensitivity symptoms do not buy a dedicated sensitivity toothpaste at all. This diagnosis — a large, symptomatic but non-purchasing population — is the documented starting point for the communications approach examined in this case. A trade feature on the Sensodyne–Grey creative partnership (a 20-year working relationship, per the publication) adds that the brand, for "a short period" around 2022, moved its marketing focus away from sensitivity messaging toward other equities, before the appointment of Ignacio Notivol Delso as VP and global business lead for Sensodyne and Pronamel led to what the source describes as sensitivity being "firmly re-established" as the focal message platform. No further public detail on the intervening campaign content from that period was located in the sources reviewed for this case.

Strategic Objective

Across the public record, Sensodyne's stated communications objective is consistently framed as condition awareness and care-seeking behavior change, not simply product promotion. The May 2025 India campaign launch materials state the objective explicitly: to deepen "consumer awareness on tooth sensitivity" and to promote "timely management of the condition," rather than allowing it to be "dismissed as a minor issue." Haleon's category lead for oral healthcare in India, Kishlay Seth, is quoted stating that the goal is to help consumers "understand the underlying causes, such as enamel erosion, and take action," explicitly targeting the gap between symptom experience and product purchase identified in the company's own market filings. The Sensodyne–Grey trade feature describes this objective at a global level as a "Condition Awareness" strategy designed to address two linked challenges: (1) maximizing the reach and effectiveness of dentist–patient conversations about sensitivity, and (2) replicating the substance of that dentist conversation at scale through mass communications where direct clinical contact is not possible. The same source states that a global creative framework, referred to internally as "Be Real," is used to standardize the structure of dental-expert commentary across markets, while allowing local teams latitude to adapt language, media choice, and cultural framing. The 2020 U.S. launch of Sensodyne Sensitivity and Gum similarly frames its campaign objective as awareness-building — "to raise awareness about sensitive teeth and gum problems" — rather than as a short-term sales-activation exercise, consistent with the longer-run, education-first objective described in the more recent India and global materials.

Campaign Architecture & Execution

Publicly documented Sensodyne sensitivity-awareness executions share a common architecture: (a) a scientific/clinical explanation of the sensitivity mechanism, (b) a human testimonial or spokesperson layer that dramatizes the everyday impact of the condition, and (c) a call to action oriented toward product trial and, in several markets, professional consultation.

United States (2020) — "Take a Bite Out of Life." GSK Consumer Healthcare's press release (July 16, 2020) announced the nationwide launch of Sensodyne Sensitivity and Gum toothpaste alongside a campaign built around actress and cookbook author Tiffani Thiessen, described in the release as a "sensitivity sufferer" who shared her own experience. The campaign used a food-centric narrative frame, tying tooth sensitivity to the disruption of shared meals and family food occasions. The release also cited a company-commissioned OnePoll survey of 2,000 U.S. adults (fielded May 10–12, 2020) to support the campaign's cultural insight about food as a connective social ritual — a disclosed and attributed data source rather than an internally generated metric.

India (2025) — Enamel Erosion Awareness Campaign. Reported by Medicircle and IMPACT (May 2025), this campaign comprised 18 films produced in nine regional languages, built around real (non-actor) consumer testimonials describing the lived experience of sensitivity. The creative explicitly explains one biological cause of the condition — enamel erosion exposing dentine and triggering nerve response — using what the source describes as "high-science visualizations." The stated intent, per Haleon's category lead, was to move consumers from dismissing sensitivity as minor toward recognizing it as a "progressive condition" warranting timely action.

Malaysia (2023) — Institutional Partnership Model. Reported by Marketing-Interactive, Haleon partnered with the Malaysian Dental Association (MDA) around the unveiling of a national oral health policy, combining brand-level awareness activity with public-health institutional endorsement. The campaign incorporated on-ground activities involving healthcare professionals, social creators, and influencers, targeting both awareness and broader oral hygiene education, including of periodontitis alongside sensitivity.

"Sensitivity Stories" with Jamie Oliver (October 2025). According to industry market-research reporting (Market.us), Sensodyne launched a campaign titled "Sensitivity Stories" in partnership with chef Jamie Oliver, again explicitly framed around raising awareness of tooth sensitivity and encouraging consumers toward daily care solutions. Beyond this description, no further verified public detail on this campaign's creative execution or market rollout was located in the sources reviewed.

Recurring execution constraint: regulatory adaptation. The Sensodyne–Grey feature documents an important cross-market execution constraint: in some countries, advertising regulations prohibit the depiction of real healthcare professionals, requiring the use of actors portraying dentists instead; in markets such as the UK, where use of real healthcare professionals is similarly restricted, the brand instead uses scientists for on-camera commentary. This is presented in the source as a structural reason why Sensodyne's messaging is not executed as a single global template but is instead locally adapted within the shared "Be Real" framework.

Positioning & Consumer Insight

Sensodyne's documented positioning centers on a stated brand purpose — to "help humanity reclaim life's small pleasures without the restrictions of sensitive teeth," per Haleon's SEC filings. This purpose statement directly reflects the underlying consumer insight repeated across multiple public sources: sensitivity is experienced by sufferers as an intermittent but recurring interruption to ordinary pleasures — eating, drinking, socializing — rather than as a standalone medical complaint people proactively seek to treat. The 2020 U.S. campaign operationalized this insight through food and shared meals; the 2025 India campaign operationalized it through testimonial storytelling about "everyday challenges." A second, more structural insight — documented in Haleon's own regulatory disclosures — is that dentist recommendation is a primary driver of category purchase, but reaches only a fraction of the symptomatic population, since not everyone with sensitivity discusses it during a dental visit or has regular dental access. The "Condition Awareness" strategy described by the Sensodyne–Grey source is a direct response to this insight: mass communications are designed to functionally substitute for, or reinforce, the clinical conversation at a scale dentist interactions alone cannot achieve. This explains the recurring creative device — across the U.S., India, and other markets — of positioning a credible expert or authentic sufferer voice, rather than a purely product-benefit advertisement, as the core communication unit.

Media & Channel Strategy

Public sources confirm a multichannel approach but disclose limited channel-level detail. The 2025 India campaign is reported to span "television, digital, print and social media platforms." The Malaysia 2023 initiative combined institutional/PR channels (partnership announcement with the national dental association) with influencer and social-creator activation described as "on-ground activities." The Sensodyne–Grey feature adds market-specific channel notes: in China, the brand is reported to use TikTok Shop as a commerce-linked channel; in Italy, an influencer partnership was used to bring a simulated "dentist experience" to consumers in public settings; in Germany, a campaign for the brand's "Repair" product line used a locally resonant creative comparison to the city's construction delays. Beyond these disclosed examples, no verified public information is available on Sensodyne's global media mix modeling, channel-level spend allocation, or paid-media budgets by market.

Business & Brand Outcomes

Haleon's audited financial disclosures provide the clearest publicly verifiable outcome data tied to the Oral Health category in which Sensodyne is the largest brand, though these figures are reported at category level rather than isolated purely to communications-driven, brand-only performance:

• FY2023: Oral Health revenue grew 6.1% on a reported basis to £3.1 billion, with organic revenue growth of 10.6%. Haleon's results statement specifically attributes double-digit organic growth to all three Oral Health "Power Brands," including Sensodyne, and links this growth to "strong brand building campaigns and activation, key innovations and geographic expansion."

  
  

• H1 2024: Oral Health revenue grew 5.9% to £1.7 billion, with organic growth of 9.9%; Sensodyne, parodontax and Centrum (across categories) were noted as growing at a double-digit organic rate as part of Haleon's "Power Brands" grouping.

  
  

• Q3 2024: Oral Health grew at a mid-single-digit organic rate globally, with Haleon's trading statement specifying "high-single digit growth in Sensodyne from innovation driving share gains" in EMEA/LatAm, and "double digit growth in Oral Health... driven by continued momentum in Sensodyne" in Asia-Pacific, with particular strength cited in India and South East Asia & Taiwan.

  
  

• FY2024: Oral Health reported revenue rose 5.6% to £3.3 billion, with organic revenue growth of 9.6%. Haleon's full-year results state that, excluding foreign exchange impact, Sensodyne revenue "grew double digit," and that the newly launched Sensodyne Clinical White variant was the "number one US Oral Health market launch in 2024," subsequently rolled out to over 10 markets. Haleon also disclosed that 71% of its overall business "gained or maintained share" in 2024, based on the Group's analysis of third-party market data (IQVIA, IRI, and Nielsen, per the company's own methodology footnote).

  
  

• Brand ranking: Across multiple SEC filings tied to the 2022 demerger (Forms F-1, 20FR12B, 424B3, POS AM), Sensodyne is consistently and specifically described as "the number two Toothpaste brand globally and the number one dentist-recommended Toothpaste worldwide for sensitivity" — a ranking claim made directly by the company in regulatory disclosures rather than derived from a third-party report.

  
  

It is important to note that Haleon's growth disclosures are presented at the level of the Sensodyne brand and the Oral Health category as a whole, reflecting the combined effect of pricing, innovation (e.g., new product launches such as Clinical White or Pronamel Active Shield), geographic expansion, and communications activity together.

Strategic Implications

Several strategic lessons can be drawn directly from the documented record, without extrapolating beyond it.

First, the case illustrates a category-expansion logic distinct from conventional share-of-market competitive strategy. Because Haleon's own disclosures frame the addressable opportunity as converting symptomatic non-purchasers rather than winning switchers from rival sensitivity brands, the communications objective (awareness and care-seeking behavior) is structurally aligned with the commercial objective (category penetration) rather than being a separate branding exercise layered on top of a sales strategy.

Second, the brand's reliance on dentist endorsement as a foundational equity, combined with the explicit "Condition Awareness" framework of replicating dentist conversations at scale, demonstrates a model in which professional credibility is treated as a scalable communications asset — engineered into creative structure (the "Be Real" framework) rather than used only as an occasional testimonial device.

Third, the consistent tension between global brand consistency and local regulatory/cultural adaptation — dentist portrayal rules varying by market, or market-specific creative devices such as the Germany construction analogy or China's TikTok Shop integration — indicates that Sensodyne's global strategy is best understood as a shared strategic and evidentiary framework with locally executed creative expression, rather than a single global campaign asset.

Fourth, the available financial disclosures show that periods of renewed sensitivity-focused messaging (post-2022, per the Grey trade feature) coincide with several years of documented double-digit organic Oral Health growth and repeated market-share gains, though the company's own reporting attributes this jointly to campaign activation, product innovation, and geographic expansion, and a causal weighting between these factors is not disclosed.

Fifth, the case underscores a broader principle relevant to any MBA marketing analysis: publicly reported outcome metrics in categories like consumer healthcare are typically aggregated at brand or category level within audited financial disclosures, and companies rarely isolate the return on a specific communications campaign in public filings. Analysts and students should treat brand-level growth figures as indicative of overall commercial health rather than as direct proof of a single campaign's efficacy.

Discussion Questions

1. Haleon's own filings describe the addressable opportunity as converting the two-thirds of sensitivity sufferers who do not currently buy a dedicated sensitivity toothpaste. What are the strategic risks and benefits of building a communications strategy around category penetration rather than competitive share-shifting?

   
   

2. The "Be Real" framework standardizes the structure of dental-expert commentary globally while allowing local adaptation in language, regulation, and cultural framing (e.g., Germany, Italy, China). What criteria should a global brand use to decide which elements of a campaign framework must remain fixed versus locally adaptable?

   
   

3. Regulatory restrictions in markets like the UK prevent the use of real healthcare professionals in advertising, requiring the use of scientists or actors instead. How might this constraint affect the perceived credibility of a campaign built around clinical authority, and how could a brand mitigate that risk?

   
   

4. Haleon's financial disclosures attribute Oral Health growth jointly to "brand building campaigns and activation, key innovations, and geographic expansion." As a marketing analyst without access to internal attribution data, how would you approach estimating the relative contribution of communications strategy versus product innovation to reported brand growth?

   
   

5. The case shows that Sensodyne temporarily moved away from sensitivity-focused messaging before reinstating it as the core platform. What organizational or market signals might justify a brand deprioritizing its core category-awareness message, and what risks does that shift carry for a brand whose primary equity is condition education?